CROI 2020 Abstract eBook

Abstract eBook

Oral Abstracts

88 ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES Charles Dobard 1 , M. Melissa Peet 2 , Kenji Nishiura 1 , Angela Holder 1 , Onkar N. Singh 2 , Timothy J. McCormick 2 , James Mitchell 1 , George Khalil 1 , Gerardo Garcia- Lerma 1 , Vivek Agrahari 2 , Pardeep Gupta 3 , Sriramakamal Jonnalagadda 3 , Walid Heneine 1 , Gustavo Doncel 2 , Meredith Clark 2 1 CDC, Atlanta, GA, USA, 2 CONRAD, Arlington, VA, USA, 3 University of the Sciences, Philadelphia, PA, USA Background: Topical products for HIV prevention that can be administered on-demand, either pre- or post-viral exposure, remain an advantageous regimen for end-users that have infrequent or clustered intercourse or are unable to take daily pills. CONRAD has developed a topical insert co-formulated with tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG) to provide end-users a flexible on-demand dosing regimen that may align with their needs and lifestyle. Recently, we showed in a macaque model that mimics vaginal HIV transmission in women that a vaginal insert containing a fixed-dose combination of TAF and EVG was highly effective in preventing SHIV infection when administered 4 hours before virus exposure. Here, we investigated the efficacy of the same TAF/EVG insert when administered 4 hours after SHIV exposure. Methods: Normal cycling pigtail macaques (n=11) were exposed vaginally to SHIV162P3 once-weekly for 13 weeks. Six macaques received TAF/EVG inserts (20/16 mg) and 5 received a placebo. Inserts were placed in the posterior vagina near the cervix 4 hours after each SHIV exposure. Infection was monitored weekly by serology and RT-PCR of SHIV RNA in plasma. The concentrations of TAF, TFV, and EVG in plasma and TFV-DP in PBMCs were measured at 4 hours in a second group of 6 macaques that received the same TAF/EVG inserts once- weekly for 13 consecutive weeks. Results: Four of the 5 macaques that received placebo inserts became infected with SHIV after a median of 4 challenges (range 2-13). In contrast, all 6 macaques that received TAF/EVG inserts 4h after SHIV exposure remained protected after 13 challenges and a 20-week follow-up period (p=0.009; log-rank test). The calculated PEP efficacy of TAF/EVG inserts was 100%. Of the 78 plasma specimens collected 4h post insert dosing, EVG was only detected in 1 sample (15 ng/ml); none had detectable TFV or TAF. Conversely, TFV-DP was detected in 42/59 PBMC samples; median level in samples with detectable TFV-DP was 147.5 [range=15-993] fmol/10 6 cells. Conclusion: Vaginal administration of a single TAF/EVG insert several hours after virus exposure fully protected macaques against SHIV infection, thus increasing flexibility and expanding our established window of protection to 4 hours before or after sex. The observed high levels of TFV-DP in PBMCs by topical delivery of TAF is unique and may have contributed to protection. Our data support the clinical development of TAF/EVG inserts for on-demand PrEP/PEP for HIV prevention. 89LB WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 Martin Markowitz 1 , Agegnehu Gettie 2 , Leslie St. Bernard 1 , James Blanchard 2 , Brooke Grasperge 2 , Kerry Fillgrove 3 , Lingling Xue 3 , Neal Dube 3 , Daria Hazuda 3 , Jay Grobler 3 1 Aaron Diamond AIDS Research Center, New York, NY, USA, 2 Tulane National Primate Research Center, Covington, LA, USA, 3 Merck & Co, Inc, Kenilworth, NJ, USA Background: Islatravir (ISL, MK-8591, EFdA) is a novel nucleoside reverse transcriptase translocation inhibitor with robust antiviral activity and has demonstrated efficacy as weekly oral PrEP in the SHIV/Rhesus macaque (RM) rectal challenge model for doses ranging from 0.1 mg/kg to 3.9 mg/kg. We tested ISL’s efficacy as post-exposure prophylaxis (PEP) in the SIV/RM IV challenge model. Methods: 12 RM were challenged IV with 10 AID50 of SIVmac251. After 24 hr, 6 animals received 3.9 mg/kg ISL and 6 animals served as untreated controls. Treated animals in Stage I received a total of 4 weekly oral doses of ISL and were monitored for SIV infection for 7 wk after the 4th dose of ISL. In Stage II uninfected animals from Stage I were challenged as in Stage I and beginning 24h later 3 weekly oral doses of ISL at 3.9 mg/kg was initiated. Animals were monitored for 7 wk after the 3rd dose of ISL. Uninfected animals entered Stage III and were similarly challenged and treatment initiated at 24 h with 2 weekly oral doses of ISL at 3.9 mg/kg and animals monitored for 7 wk after the 2nd dose of ISL. Finally in Stage IV, uninfected animals were challenged IV and 24 hours later treated with a single oral dose of ISL at 3.9 mg/kg and followed for 7 wk. Animals were monitored for infection using RT-PCR and proviral

DNA amplification. Virus-specific antibody responses were measured using a commercial assay. Plasma ISL levels as well as ISL-triphosphate (ISL-TP) levels in PBMC were measured longitudinally. Results: All untreated control animals were viremic 7 days after IV challenge with SIVmac251. 6/6 treated animals were completely protected in Stages I-III (Fisher’s exact test P=0.0022). ISL-TP levels became undetectable in PBMC 3 weeks on average after the last ISL oral dose. In Stage IV, two of 6 animals became infected with wild type SIVmac251, one with viremia at day 14 ([ISL-TP] < 0.02 pmol/10 6 PBMCs ) and another at day 49 (Fisher’s exact test P=0.06). Conclusion: As few as 2 weekly oral doses of ISL at 3.9 mg/kg given 24h after IV challenge with SIVmac251 completely prevented infection. However, a single ISL dose 24h after IV challenge failed to provide statistically significant protection. As the ISL-TP T 1/2 in human PBMCs (79-214 hr) is substantially longer than RM (50 hr), it is conceivable that a single low oral dose given within 24 hours of HIV exposure may provide effective PEP. These results support the potential utility of ISL as a simplified PEP agent. 90 PHASE I PLACEBO-CONTROLED SAFETY, PK, AND PD STUDY OF MB66 ANTI-HIV AND ANTI-HSV FILM Susan Cu-Uvin 1 , Thomas Moench 2 , Joseph A. Politch 3 , Karen T. Tashima 1 , Jai G. Marathe 3 , Kate M. Guthrie 1 , Howard Cabral 3 , Tara J. Nyhuis 2 , Miles Brenna 2 , Larry Zeitlin 2 , Hans M. Spiegel 4 , Kenneth H. Mayer 5 , Kevin Whaley 2 , Deborah Anderson 3 1 Brown University, Providence, RI, USA, 2 Mapp Biopharmaceutical, Inc, San Diego, CA, USA, 3 Boston University, Boston, MA, USA, 4 NIH, Rockville, MD, USA, 5 Harvard University, Cambridge, MA, USA Background: Monoclonal antibodies(mAbs)show promise as multipurpose prevention technology.The MB66 intravaginal film contains 10 mg each of anti-HIV(VRC01) and anti-HSV(HSV8) mAbs to provide protection against two incurable viral infections. Methods: The active film or vehicle control filmwas randomly assigned at a 1:1 ratio to 29 healthy sexually abstinent women who were instructed to insert 1 film daily for 7 days.Visits and clinical sampling occurred predose at 1, 4, 24 hrs after the 1st dose and 24 hrs, 6-10 days after the 7th dose. Cervicovaginal lavage samples (CVLs) were assayed by Luminex for 16 cytokines that have been associated with HIV transmission,by TZM-bl assay for HIV neutralization[strains:Q23-1 (R5 clade A), BaL (R5 clade B),and LAI (X4 clade B)],and by Plaque Reduction NeutralizationTest for HSV-2 neutralization [HSV-2 strain G].CVLs and TearFlo samples(4 vaginal sites)were assessed by ELISA for VRC01 and HSV8 mAb concentrations. Results: There were 45 AEs;19 were deemed related to study product, but were balanced between active and placebo film (p’s=1.0).There were no serious AEs(SAEs) and no significant differences in levels of proinflammatory cytokines, Nugent Scores,vaginal pH between Active and Placebo film groups(p’s>0.10). Acceptability and willingness to use the product were judged to be high by post-use ACASI questionnaire.Concentrations of VRC01 and HSV8 increased significantly in vaginal secretions following insertion of Active film.Antibody levels in TearFlo samples peaked at 1 hr post-dosing (median:35 µg/mL) but remained significantly elevated at 24 hours post 1st and 7th film. (median: ~ 1.8 µg/mL). In light of an estimated dilution factor of 35 for the TearFlo samples,the extrapolated VRC01 concentrations range from 63-1,225 times IC 50 for VRC01(~1 µg/mL).CVLs from the active film group, collected 24 hr after 1st film and 7th films,significantly neutralized all 3 HIV strains and HSV-2. Conclusion: Repeated doses of MB66 filmwas safe and tolerated.Significant HIV-1 and HSV-2 neutralization (ex vivo) was observed at 24 hrs,7 films. Antibody levels in vagina had concentrations consistent with protection for up to 24 hrs.

Oral Abstracts

31

CROI 2020

Made with FlippingBook - professional solution for displaying marketing and sales documents online